-
Advancing Precision Medicine in Diffuse Large B Cell Lymphoma: Insights from the GUIDANCE-01 Trial
Diffuse large B cell lymphoma (DLBCL) stands as the most prevalent subtype among non-Hodgkin lymphomas, presenting unique challenges in its treatment due to its genetic heterogeneity.The GUIDANCE-01 trial, designed as…
-
Excessive Serine Impairs Megakaryopoiesis and Thrombopoiesis in Multiple Myeloma
Thrombocytopenia, a major complication in multiple myeloma (MM) patients, is associated with poor prognosis. However, the factors contributing to thrombocytopenia in MM and their significance are not well understood. Recent…
-
Ex utero Monkey Embryogenesis: Advancements in In vitro Culture System”
This is groundbreaking research. Researchers have developed an embedded three-dimensional (3D) culture system for monkey embryos, enabling in vitro culturing up to 25 days post-fertilization, overcoming previous limitations. The Enhanced Monkey Ex Utero…
-
Anti-GPRC5D CAR-TCell Therapy: A Breakthrough for Multiple Myeloma
Multiple myeloma (MM) is a challenging hematologic cancer characterized by uncontrollable plasma cell proliferation in the bone marrow. Despite advancements in MM treatments, relapse or refractory cases are common. Chimeric…
-
The Pan-Cancer Dynamics of Natural Killer Cells: Insights into Heterogeneity and Dysfunction
The immune system’s frontline defenders, Natural Killer (NK) cells, play a pivotal role in the innate immune response against tumor progression. To deepen our understanding of their intricacies within the…
-
ESMO China Voice | Professor Xiaojia Wang: Aromatase Inhibitor Treatment for mBC Progression? Anlotinib Combined with Fulvestrant Offers New Hope
Editor’s Note: Hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for over 70% of all breast cancers[1]. The use of CDK4/6 inhibitors has brought…
-
Professor Ying Fan: Evolution of HR+/HER2- Early Breast Cancer Adjuvant Treatment Strategies and Risk Stratification—Based on the Chinese Perspective
Editor’s Note Breast cancer is the most common malignancy in women, with an increasing incidence in recent years. HR+/HER2- breast cancer accounts for approximately 70% of all breast cancer cases,…
-
ESMO Big Shot Interview | Professor Feng Wang: Significant Efficacy of Sintilimab Combined with Apatinib and Bevacizumab in the Treatment of MSS/pMMR Metastatic Colorectal Cancer, Promising Future
The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain from October 20 to 24. The Oncology Frontier Reporting Team delved into the frontiers of international advancements, witnessing the progress of China’s anti-cancer efforts on the global stage. Professor Feng Wang from Sun Yat-sen University Cancer Center presented an important…
Connecting Medical Expertise through Media